{"id":"mitolactol","rwe":[{"pmid":"29257158","year":"2017","title":"[Anticancer drug research in Hungary, 1950-2000].","finding":"","journal":"Magyar onkologia","studyType":"Clinical Study"},{"pmid":"20842409","year":"2010","title":"Induction chemotherapy response and recurrence rates in correlation with N0 or N+ stage in oral squamous cell cancer (OSCC).","finding":"","journal":"Cancer metastasis reviews","studyType":"Clinical Study"},{"pmid":"19757193","year":"2010","title":"Neoadjuvant chemotherapy: does it have benefits for the surgeon in the treatment of advanced squamous cell cancer of the oral cavity?","finding":"","journal":"Pathology oncology research : POR","studyType":"Clinical Study"},{"pmid":"16774296","year":"2006","title":"Treatments for astrocytic tumors in children: current and emerging strategies.","finding":"","journal":"Paediatric drugs","studyType":"Clinical Study"},{"pmid":"15330214","year":"2004","title":"Failure of alkylating agents to improve induction chemotherapy of oropharyngeal squamous cell cancer.","finding":"","journal":"Anticancer research","studyType":"Clinical Study"}],"tags":[{"label":"mitolactol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Alkylating Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Alkylating","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"elobromol","offLabel":[],"synonyms":["dibromodulcitol","dibromdulcit","dibromogalactitol","elobromol","mitolactol"],"timeline":[],"approvals":[],"brandName":"Elobromol","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"mitolactol","explanation":"Think of it like a key that fits into a lock, but instead of unlocking a door, it blocks a specific process that cells use to function. This can be helpful in treating certain conditions, but it's a complex process that needs more research to fully understand. By blocking this process, elobromol may be able to slow down or stop the progression of a disease.","oneSentence":"Elobromol works by inhibiting cellular processes, although the exact target and mechanism are unknown.","technicalDetail":"Elobromol's mechanism of action is thought to involve the inhibition of cellular processes, although the specific target and molecular details are currently unknown."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/857","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MITOLACTOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MITOLACTOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:32:45.714934","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:42:23.128100+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"mitolactol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00002620","phase":"PHASE3","title":"Radiation Therapy in Treating Patients With Brain Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1994-11","conditions":["Brain and Central Nervous System Tumors"],"enrollment":212,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"LJ2P1SIK8Y","CHEBI":"CHEBI:135311","INN_ID":"3143","UMLSCUI":"C0026252","ChEMBL_ID":"CHEMBL2104612","DRUGBANK_ID":"DB12916","PUBCHEM_CID":"5284380","MESH_DESCRIPTOR_UI":"D008936"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":53,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2017 Dec 18","pmid":"29257158","title":"[Anticancer drug research in Hungary, 1950-2000].","journal":"Magyar onkologia"},{"date":"2010 Dec","pmid":"20842409","title":"Induction chemotherapy response and recurrence rates in correlation with N0 or N+ stage in oral squamous cell cancer (OSCC).","journal":"Cancer metastasis reviews"},{"date":"2010 Jun","pmid":"19757193","title":"Neoadjuvant chemotherapy: does it have benefits for the surgeon in the treatment of advanced squamous cell cancer of the oral cavity?","journal":"Pathology oncology research : POR"},{"date":"2006","pmid":"16774296","title":"Treatments for astrocytic tumors in children: current and emerging strategies.","journal":"Paediatric drugs"},{"date":"2004 Jul-Aug","pmid":"15330214","title":"Failure of alkylating agents to improve induction chemotherapy of oropharyngeal squamous cell cancer.","journal":"Anticancer research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Elobromol, also known as MITOLACTOL, is a small molecule drug in the mitolactol class. Its exact target and mechanism of action are unknown, but it is believed to work by inhibiting cellular processes. Elobromol's commercial status and approved indications are unclear, and it is not known whether it is patented or available as a generic. Further research is needed to fully understand its effects and potential uses. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are also unknown.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:42:23.128100+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}